基于算法的、仅使用G-CSF的动员方案，并根据CD34计数提前使用普乐沙福，实现了100%的采集成功率，促进了早期植入，减少了普乐沙福的使用，并避免了动员失败。这种方法避免了化疗的毒性反应，优化了普乐沙福的使用，防止了移植时间的延迟。 图1。基于CD34 ...

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. Th ...

The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL) ...

Spectrum Pharmaceuticals Inc. celebrated a long-awaited win with the U.S. FDA’s approval late Sept. 9 of novel G-CSF drug eflapegrastim, cleared for use in chemotherapy-induced neutropenia nearly four ...

When the use of prophylactic granulocyte-colony stimulating factor (G-CSF) to reduce febrile neutropenia (FN) was decreased in patients receiving chemotherapy for breast cancer, it led to a more than ...

- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...